Literature DB >> 10334038

The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells.

T Satoh1, Y Hoshikawa, Y Satoh, T Kurata, T Sairenji.   

Abstract

To understand the mechanism by which Epstein-Barr virus (EBV) is activated in Akata cells by cross-linking of surface immunoglobulin, the interaction between mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and EBV activation was investigated. Immunoblotting using an anti-phosphoMAPK antibody (Ab) revealed that anti-IgG Ab induced rapid phosphorylation of MAPK in the cells. The phosphorylation was inhibited by MAPK/ERK kinase specific inhibitor, PD98059. The expressions of the EBV immediate early BZLF1 mRNA and its protein product ZEBRA, and early antigen were also inhibited by the inhibitor. These results indicate that MAPK is involved in the pathways of EBV activation.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10334038     DOI： 10.1023/a:1008021402908

Source DB:  PubMed          Journal:  Virus Genes        ISSN： 0920-8569            Impact factor:   2.332


  40 in total

1.  Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.

Authors:  J Luka; B Kallin; G Klein
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

2.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

Review 4.  The MAPK signaling cascade.

Authors:  R Seger; E G Krebs
Journal:  FASEB J       Date:  1995-06       Impact factor: 5.191

Review 5.  The mitogen-activated protein kinase signal transduction pathway.

Authors:  R J Davis
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

6.  Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells.

Authors:  R Seger; N G Ahn; J Posada; E S Munar; A M Jensen; J A Cooper; M H Cobb; E G Krebs
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

Review 7.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

8.  Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.

Authors:  T Sairenji; Y Hinuma
Journal:  Int J Cancer       Date:  1980-09-15       Impact factor: 7.396

9.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

10.  Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA.

Authors:  M Daibata; R E Humphreys; T Sairenji
Journal:  Virology       Date:  1992-06       Impact factor: 3.616
View more
  8 in total

1.  EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells.

Authors:  Jin Qiu; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-10       Impact factor: 11.205

2.  Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.

Authors:  R Goswami; S Gershburg; A Satorius; E Gershburg
Journal:  Antiviral Res       Date:  2012-10-08       Impact factor: 5.970

3.  Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk.

Authors:  K C Simon; I A F van der Mei; K L Munger; A Ponsonby; J Dickinson; T Dwyer; P Sundström; A Ascherio
Journal:  Neurology       Date:  2010-04-07       Impact factor: 9.910

4.  CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.

Authors:  Lingbing Tan; Chaocan Zhang; Julien Dematos; Linlin Kuang; Jae U Jung; Xiaozhen Liang
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

5.  Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.

Authors:  H Fahmi; C Cochet; Z Hmama; P Opolon; I Joab
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.

Authors:  Helen Bryant; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Distinct patterns of mitogen-activated protein kinase phosphorylation and Epstein-Barr virus gene expression in Burkitt's lymphoma cell lines versus B lymphoblastoid cell lines.

Authors:  Tomohisa Satoh; Makoto Fukuda; Takeshi Sairenji
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

8.  Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells.

Authors:  Xiangrong Gao; Haoran Wang; Takeshi Sairenji
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.